British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

CA Lamb, NA Kennedy, T Raine, PA Hendy, PJ Smith… - Gut, 2019 - gut.bmj.com
Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission

J Burisch, M Zhao, S Odes, P De Cruz… - The Lancet …, 2023 - thelancet.com
The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase
worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease …

Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease

LM Chen, CH Bao, Y Wu, SH Liang, D Wang… - Journal of …, 2021 - Springer
Inflammatory bowel disease (IBD), which mainly includes ulcerative colitis (UC) and Crohn's
disease (CD), is a group of chronic bowel diseases that are characterized by abdominal …

The necessity–concerns framework predicts adherence to medication in multiple illness conditions: A meta-analysis

H Foot, A La Caze, G Gujral, N Cottrell - Patient education and counseling, 2016 - Elsevier
Objective This meta-analysis investigated whether beliefs in the necessity and concerns of
medicine and the necessity–concerns differential are correlated with medication adherence …

[HTML][HTML] Medication adherence in inflammatory bowel disease

W Chan, A Chen, D Tiao, C Selinger… - Intestinal …, 2017 - synapse.koreamed.org
Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory condition with
intestinal and extraintestinal manifestations. Medications are the cornerstone of treatment of …

A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases

E Vangeli, S Bakhshi, A Baker, A Fisher, D Bucknor… - Advances in …, 2015 - Springer
Background Non-adherence impacts negatively on patient health outcomes and has
associated economic costs. Understanding drivers of treatment adherence in immune …

[HTML][HTML] Selective JAK1 inhibitors for the treatment of inflammatory bowel disease

OH Nielsen, TL Boye, J Gubatan, D Chakravarti… - Pharmacology & …, 2023 - Elsevier
Janus kinase (JAK) inhibitors, also known as jakinibs, are third-generation oral small
molecules that have expanded the therapeutic options for the management of chronic …

Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation?

CD Moulton, P Pavlidis, C Norton… - Clinical & …, 2019 - academic.oup.com
Depressive symptoms are reported by more than 20% of people with inflammatory bowel
disease (IBD), while sleep difficulties and fatigue are even more common. Co-morbid …

JAK1 inhibition and inflammatory bowel disease

C Harris, JRF Cummings - Rheumatology, 2021 - academic.oup.com
Primary non-response and secondary loss of response remain a significant issue with the
currently available treatment options for a significant proportion of patients with inflammatory …

Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD

PS Dulai, CA Siegel, JF Colombel, WJ Sandborn… - Gut, 2014 - gut.bmj.com
Methods To construct this review article, we performed a systematic review of the literature to
identify relevant studies comparing anti-TNF monotherapy to combination therapy with an …